69 related articles for article (PubMed ID: 29095654)
21. Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study.
Huang CE; Lee KD; Chang JJ; Tzeng HE; Huang SH; Yu LH; Chen MC
Oncologist; 2024 Jan; 29(1):e81-e89. PubMed ID: 37561957
[TBL] [Abstract][Full Text] [Related]
22. Future treatment of Diabetes - Tyrosine Kinase inhibitors.
S AK; Patel SS; Patel S; Parikh P
J Diabetes Metab Disord; 2023 Jun; 22(1):61-71. PubMed ID: 37255821
[TBL] [Abstract][Full Text] [Related]
23. Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies.
Cheng F; Xu Q; Li Q; Cui Z; Li W; Zeng F
Front Oncol; 2023; 13():1113462. PubMed ID: 36814818
[TBL] [Abstract][Full Text] [Related]
24. A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia.
Ahmed K; Kaddoura R; Yassin MA
Front Med (Lausanne); 2022; 9():1025392. PubMed ID: 36569145
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes.
Althubiti M
Saudi J Med Med Sci; 2022; 10(3):183-191. PubMed ID: 36247049
[TBL] [Abstract][Full Text] [Related]
26. Black Truffle Extract Exerts Antidiabetic Effects through Inhibition of Inflammation and Lipid Metabolism Regulation.
Wu Z; Jayachandran M; Cheang WS; Xu B
Oxid Med Cell Longev; 2022; 2022():6099872. PubMed ID: 35251478
[TBL] [Abstract][Full Text] [Related]
27. Lifelong TKI therapy: how to manage cardiovascular and other risks.
Mauro MJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):113-121. PubMed ID: 34889360
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.
Chen MT; Huang ST; Lin CW; Ko BS; Chen WJ; Huang HH; Hsiao FY
Oncologist; 2021 Nov; 26(11):974-982. PubMed ID: 34418220
[TBL] [Abstract][Full Text] [Related]
29. New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review.
Jo A; Scarton L; O'Neal LJ; Larson S; Schafer N; George TJ; Munoz Pena JM
Cancer Med; 2021 Jan; 10(2):439-446. PubMed ID: 33355998
[TBL] [Abstract][Full Text] [Related]
30. How to manage CML patients with comorbidities.
Cortes J
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):237-242. PubMed ID: 33275749
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors-A Single-Centre Retrospective Study.
Varga A; Tilea I; Petra DN; Tilinca MC; Gliga ML; Demian S
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33053860
[TBL] [Abstract][Full Text] [Related]
32. Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells.
Na YJ; Yu ES; Kim DS; Lee DH; Oh SC; Choi CW
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S196-S206. PubMed ID: 32241082
[TBL] [Abstract][Full Text] [Related]
33. BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Haguet H; Douxfils J; Chatelain C; Graux C; Mullier F; Dogné JM
TH Open; 2018 Jan; 2(1):e68-e88. PubMed ID: 31249931
[TBL] [Abstract][Full Text] [Related]
34. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
35. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
[TBL] [Abstract][Full Text] [Related]
36. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Miura M
Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
[TBL] [Abstract][Full Text] [Related]
39. Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.
Franklin M; Burns L; Perez S; Yerragolam D; Makenbaeva D
Curr Med Res Opin; 2018 Feb; 34(2):353-360. PubMed ID: 29095654
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
